| Literature DB >> 30271485 |
Wen-Zhao Sun1, Li Chen1, Xin Yang1, Bin Wang1, Xiao-Wu Deng1, Xiao-Yan Huang1.
Abstract
Purpose: To investigate the difference in treatment plan quality of volumetric modulated arc treatment (VMAT) for esophageal carcinoma with flattening filter beam (FF) and flattening filter free beam (FFF). Material and methods: A total of fifty-six treatment plans were generated for twenty eight esophageal carcinoma patients with flattening filter beam and flattening filter free beam, using same optimal parameters. The homogeneity index (HI) and conformal index (CI) of targets, and some special points on Dose-Volume Histogram (DVH) curves were used to compare the plan quality. The coverage volumes of 45 Gy, 30 Gy and 20 Gy outside targets (V45Gy, V30Gy and V20Gy ) were used to compare the targets peripheral dose. The MU numbers, measured delivery time and averaged dose rates were used to evaluate the delivery efficiency of treatment plans.Entities:
Keywords: esophageal carcinoma; flattening filter free beam; peripheral dose; plan quality
Year: 2018 PMID: 30271485 PMCID: PMC6160692 DOI: 10.7150/jca.26044
Source DB: PubMed Journal: J Cancer ISSN: 1837-9664 Impact factor: 4.207
Patient's characteristics and target volume.
| Patients | Staging | Gender | Age | PTV1 | PTV2 |
|---|---|---|---|---|---|
| 1 | T2N1M0 | M | 79 | 125.24 | 410.48 |
| 2 | T2N1M0 | M | 51 | 179.855 | 776.235 |
| 3 | T2N3M0 | M | 53 | 126.425 | 736.19 |
| 4 | T2N1M0 | M | 68 | 117.39 | 447.895 |
| 5 | T2N1M1 | M | 73 | 153.81 | 485.195 |
| 6 | T3N1M1 | M | 51 | 136.54 | 452.54 |
| 7 | T2N1M1 | M | 65 | 183.215 | 602.45 |
| 8 | T3N0M0 | M | 56 | 445.98 | 903.175 |
| 9 | T2N3M0 | M | 61 | 318.14 | 645.775 |
| 10 | T3N1M1 | M | 58 | 282.46 | 823.08 |
| 11 | T3NIM0 | M | 49 | 184.98 | 611.405 |
| 12 | T2N1M1 | M | 51 | 502.045 | 961.765 |
| 13 | T2N1M0 | M | 64 | 91.475 | 572.33 |
| 14 | T2N3M0 | M | 64 | 149.155 | 754.925 |
| 15 | T2N1M0 | M | 61 | 286.28 | 804.935 |
| 16 | T4N0M0 | M | 59 | 225.27 | 661.485 |
| 17 | T3N1M1 | M | 45 | 82.031 | 644.185 |
| 18 | T4N1M0 | M | 62 | 125.895 | 570.99 |
| 19 | T3N1M0 | F | 49 | 135.765 | 616.805 |
| 20 | T2N1M0 | M | 75 | 54.685 | 443.09 |
| 21 | T3N2M0 | M | 78 | 52.975 | 192.575 |
| 22 | T3N1M1 | M | 63 | 101.3 | 642.26 |
| 23 | T4N1M0 | M | 68 | 200.68 | 701.775 |
| 24 | T2N1M0 | M | 67 | 418.695 | 975.74 |
| 25 | T3N3M0 | M | 57 | 91.605 | 449.025 |
| 26 | T4N1M0 | M | 79 | 145.1 | 526.84 |
| 27 | T3N1M1 | M | 66 | 84.085 | 472.97 |
| 28 | T3N1M1 | M | 60 | 62.34 | 509.59 |
| Mean | 61.8 | 184.4 | 621.3 |
Averaged over 28 patients DVH parameters, homogeneity, uniformity indices for the PTVs and OAR DVH parameters with p- and t- values for comparison.
| Parameters | 6 FF-Plan | 6 FFF-Plan | t | Δ(%) | ||
|---|---|---|---|---|---|---|
| PTVs dose | PTV1-D2%(cGy) | 6416.3±93.0 | 6420.4±78.7 | 0.578 | -0.56 | 0.08% |
| PTV1-D98%(cGy) | 5933.0±102.5 | 5925.1±104.5 | 0.478 | 0.72 | -0.13% | |
| PTV1-V95 (%) | 99.7±0.5 | 99.6±0.5 | 0.619 | -0.50 | -0.1% | |
| PTV1-V100 (%) | 95.95±2.9 | 95.8±3.0 | 0.655 | 0.45 | -0.15% | |
| HI | 1.06±0.02 | 1.060±0.02 | 0.475 | -0.72 | 0.14% | |
| CI95% | 0.453±0.13 | 0.451±0.12 | 0.566 | 0.58 | -0.43% | |
| PTV2-D98% (cGy) | 4917.5±133.44 | 4869.3±138.1 | 0.015 | 2.60 | -0.98% | |
| PTV2-V95 (%) | 98.94±0.7 | 98.7±0.9 | 0.088 | 1.77 | -0.24% | |
| PTV2-V100 (%) | 96.8±2.0 | 96.1±2.2 | 0.008 | 2.88 | -0.7% | |
| CI95% | 0.618±0.05 | 0.643±0.05 | 0.000 | -4.99 | 3.98% | |
| OARs dose | ||||||
| V30Gy(%) | 12.4±4.1 | 11.7±3.5 | 0.008 | 2.85 | -0.64% | |
| V20Gy(%) | 24.8±7.6 | 24.3±6.5 | 0.240 | 1.20 | -0.5% | |
| V10Gy(%) | 52.3±14.3 | 52.4±14.0 | 0.883 | -0.15 | 0.16% | |
| V40Gy(%) | 12.1±9.4 | 10.6±8.8 | 0.008 | 2.88 | -1.48% | |
| V30Gy(%) | 25.3±19.4 | 23.1±18.3 | 0.013 | 2.67 | -2.16% | |
| Dmean(cGy) | 1901.8±1010.9 | 1840.6±1015.6 | 0.008 | 2.85 | -3.22% | |
| D1cc(cGy) | 4217.9±238.8 | 4210.7±221.5 | 0.638 | 0.48 | -0.17% | |
| Peripheral doses volume | V45Gy(cc) | 789±440 | 738±414 | 0.000 | 4.77 | -6.46% |
| V30Gy(cc) | 1984±804 | 1822±718 | 0.000 | 4.48 | -8.18% | |
| V20Gy(cc) | 3510±1213 | 3355±1129 | 0.000 | 4.28 | -4.40% | |
| Delivery efficiency | MUs | 594.5.19±150.5 | 724.2±191.3 | 0.000 | -7.87 | 21.83% |
| Time | 109.1±12.8 | 96.1±9.93 | 0.000 | 10.58 | -11.9% | |
| Mean Dose Rate | 323.3±47.72 | 424.5±82.5 | 0.000 | -10.4 | 31.3% |
Fig 1Dose distributions from VMAT of patient 3 with FF beam (Left) and FFF beam (Right).
Fig 2Cumulative DVHs for patients 3 for PTV1, PTV2,lungs,heart, spinal cord and normal tissue (body minus PTV2) obtained in FF beam VMAT plan(solid lines) and FFF beamVAMT plan (dash lines).